Concord Asset Management LLC VA Purchases 972 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Concord Asset Management LLC VA raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 75.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,259 shares of the biopharmaceutical company's stock after acquiring an additional 972 shares during the period. Concord Asset Management LLC VA's holdings in Regeneron Pharmaceuticals were worth $1,328,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. TD Private Client Wealth LLC grew its position in Regeneron Pharmaceuticals by 9.6% during the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after buying an additional 15 shares in the last quarter. Adirondack Trust Co. boosted its holdings in shares of Regeneron Pharmaceuticals by 4.2% in the 1st quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock valued at $286,000 after purchasing an additional 18 shares in the last quarter. Prestige Wealth Management Group LLC lifted its stake in shares of Regeneron Pharmaceuticals by 23.2% in the 4th quarter. Prestige Wealth Management Group LLC now owns 101 shares of the biopharmaceutical company's stock valued at $72,000 after acquiring an additional 19 shares during the last quarter. Kingswood Wealth Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 1.8% in the 1st quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after acquiring an additional 19 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV lifted its stake in shares of Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after acquiring an additional 19 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Stock Down 1.5%

REGN stock traded down $8.41 during mid-day trading on Friday, reaching $541.59. 718,466 shares of the company traded hands, compared to its average volume of 923,692. The stock has a market cap of $58.47 billion, a price-to-earnings ratio of 13.80, a P/E/G ratio of 2.03 and a beta of 0.33. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The firm's 50 day moving average price is $544.14 and its 200 day moving average price is $616.16.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 15.27% and a net margin of 31.94%. The firm had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $3.40 billion. During the same period in the prior year, the business earned $9.55 EPS. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Tuesday, May 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.96%.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Truist Financial decreased their price target on Regeneron Pharmaceuticals from $975.00 to $940.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. UBS Group increased their price target on Regeneron Pharmaceuticals from $560.00 to $584.00 and gave the stock a "neutral" rating in a report on Friday, July 11th. BMO Capital Markets decreased their price target on Regeneron Pharmaceuticals from $800.00 to $600.00 and set an "outperform" rating for the company in a report on Monday, June 2nd. Finally, Morgan Stanley reduced their target price on Regeneron Pharmaceuticals from $755.00 to $754.00 and set an "overweight" rating for the company in a research note on Thursday, July 10th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $823.54.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.